Follistatin 315
Activin-Binding Protein, FSH-Suppressing Protein, FST-315, FS-315
Follistatin-315 is the predominant circulating isoform of follistatin, a glycoprotein that binds and neutralizes TGF-β family members like myostatin and activin to promote muscle growth and regulate various physiological processes.
Completed
NA
NCT02498431
Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention
424 General Military Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NA
NCT06240039
Direct Versus Indirect Effect of Amino Acids on Hepatokines
University of Copenhagen
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT01477073
Multiple Dose FSH-GEX(TM) in Healthy Volunteers
Glycotope GmbH
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT04064060
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
Celgene
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT00100893
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
City of Hope Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT05193396
Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment
Marianne Andersen
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT02172716
Disruption of Immune Homeostasis in Type 2 Diabetics With Generalized Chronic Periodontitis
University of Sao Paulo
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT05589129
Whey Protein Supplementation in High School Athletes
University of Utah
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NCT06730958
Evaluation of Serum Follistatin-Like Protein 1 Levels in Behcet's Disease and Its Association With Disease Activity
Assiut University
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT03682484
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort
Astellas Pharma Global Development, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT01112358
Lutropin Alfa in Women at Risk of Poor Response
Merck KGaA, Darmstadt, Germany
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT04206618
Circulating Myokine Levels and Bone Metabolism
424 General Military Hospital
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT05627440
A SkeleTal Muscle Recovery Intervention With Dietary Protein in Heart Failure
Tufts Medical Center
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT06683222
Mediating Role of Myokines in the Dialogue Between Muscle and Bone Tissue in a Population of Healthy Women Aged 20-89 Years
Centre Hospitalier Universitaire de Nīmes
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
NCT04170010
Long Term Effects of Weight Loss on Post-prandial Gut Hormone Responses and Meal Induced Thermogenesis
National and Kapodistrian University of Athens
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE1, PHASE2
NCT02354781
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy
Jerry R. Mendell
INTERVENTIONAL
Updated Dec 15, 2025
Unknown
PHASE2
NCT05096065
Study to Evaluate the Pharmacodynamics and Efficacy of Leuprolide Tablets (Ovarest®) in Women With Endometriosis
Enteris BioPharma Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT06660706
The Effects of Exercise Intervention on Skeletal Muscle and Other Organs in Aged Population and the Discovery of Associated Circulating Biomarkers
National Yang Ming Chiao Tung University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT04676009
Feasibility of an Acute Physical Exercise Before Treatment Infusion for Metastatic Lung Cancer Patients
Centre Leon Berard
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE1
NCT04184882
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
Astellas Pharma Inc
INTERVENTIONAL
Updated Dec 15, 2025